Day: December 16, 2024

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer. “Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.” Ms. Hensley most recently served as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics,...

VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to announce North Target drill hole results of the 2024 season from its wholly owned Thorn Project located in NW British Columbia, Canada. The Thorn Project is an underexplored copper-gold porphyry district with many large scale exploration target areas identified. HighlightsBrixton Metals’ maiden drill program at the North Target has intercepted a Mo-Cu porphyry system with mineralization starting from surface consisting of:Multiple generations of porphyry-style quartz and quartz-anhydrite veins hosting molybdenite, pyrite, and chalcopyrite accompanied by potassic alteration halosAnomalous copper and molybdenum within multi-kilometer scale alteration zones of phyllic,...

Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced positive topline results from a real-world evidence (RWE) study supporting ANX005 as a potential treatment...

Patrick SwindlePatrick Swindle, President and Chief Operating Officer, CoreCivic, Inc.BRENTWOOD, Tenn., Dec. 16, 2024 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that CoreCivic’s Board of Directors (the “Board”) has appointed Patrick Swindle, who currently serves as CoreCivic’s Executive Vice President and Chief Operating Officer, to President and Chief Operating Officer, effective January 1, 2025. Damon T. Hininger, who currently serves as CoreCivic’s Chief Executive Officer and President, will continue serving as CoreCivic’s Chief Executive Officer and as a member of the Board. Mr. Hininger commented, “Patrick is an exceptional leader with a wide set of skills and talents and over the years has developed an in-depth knowledge of...

VANCOUVER, British Columbia and LAS VEGAS, Dec. 16, 2024 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. (“Hydreight”or the “Company”)(TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is providing an update on VSDHOne, its Direct-to-Consumer (D2C) healthcare platform. Now fully operational in all 50 states, VSDHOne is redefining telehealth by offering businesses an unparalleled, end-to-end solution to launch their own healthcare brands—quickly, cost-effectively, and at scale. What is VSDHOne? VSDHOne provides a comprehensive telemedicine platform that empowers businesses, including MedSpas, health and wellness entrepreneurs, retailers, and pharmaceutical brands, to create D2C healthcare solutions...

NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Nevada Canyon Gold Corp (OTCQX: NGLD), a uniquely structured natural resource company, has qualified to trade on the OTCQX® Best Market. Nevada Canyon Gold Corp upgraded to OTCQX from the Pink® market. Nevada Canyon Gold Corp begins trading today on OTCQX under the symbol “NGLD.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market provides investors with a premium U.S. public market to research and trade the shares of investor-focused companies. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications...

TORONTO, Dec. 16, 2024 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. (“StorageVault”) (SVI-TSX) is pleased to announce that Deborah Robinson, ICD.D, has been appointed as a director of StorageVault as Jay Lynne Fleming has decided to step down from the Board for personal reasons. Effective December 16, 2024, the Board of Directors of StorageVault will be Benjamin Harris, Iqbal Khan, Deborah Robinson, Steven Scott, Alan Simpson and Mary Vitug. Appointment of New Independent Director to the BoardThe Board has appointed Deborah Robinson, ICD.D, as an independent director, effective December 16, 2024. Ms. Robinson brings over 25 years experience in corporate governance, executive compensation, performance measurement, and strategic consulting to CEOs and senior executives of both public and private companies and not-for-profit organizations....

Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone Company to prioritize investment into proprietary pipeline and Lilly collaboration programs, including the clinical-stage selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784) As of September 30, 2024, the Company had $267.4 million in cash, cash equivalents and marketable securities; cash runway supports Company into 2027    CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines to treat serious diseases by correcting abnormal gene expression,...